Dupilumab in Atopic Dermatitis Linked to Reduced Irritable Bowel Syndrome Risk: A Real-World Cohort Study. Levine J, Islam RK, Mo L, Kim BS, et al. Allergy 2025 Jun 25. doi: 10.1111/all.16637.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Levine J, Islam RK, Mo L, Kim BS, et al. Dupilumab in Atopic Dermatitis Linked to Reduced Irritable Bowel Syndrome Risk: A Real-World Cohort Study. Allergy 2025 Jun 25. doi: 10.1111/all.16637.
PMID: 40560741